These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
401 related articles for article (PubMed ID: 35116812)
1. Correlative analysis of gene mutation and clinical features in patients with non-small cell lung cancer. Kuang X; Xiao J; Dai LX; Zhang LH; He BX Transl Cancer Res; 2019 Jun; 8(3):736-751. PubMed ID: 35116812 [TBL] [Abstract][Full Text] [Related]
2. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective. Aggarwal A; Sharma S; Brar Z; Kumar V; Kumar A; Katara R; Mohanty SK Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714 [TBL] [Abstract][Full Text] [Related]
3. Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland. Grosse A; Grosse C; Rechsteiner M; Soltermann A Diagn Pathol; 2019 Feb; 14(1):18. PubMed ID: 30744664 [TBL] [Abstract][Full Text] [Related]
4. [Correlation between common driver gene variations and clinicopathological typing in lung adenocarcinoma]. Ma XL; Jia RN; Han K; Zhang YX Zhonghua Bing Li Xue Za Zhi; 2024 Jun; 53(6):578-584. PubMed ID: 38825903 [No Abstract] [Full Text] [Related]
5. Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis. Chen J; Lu W; Chen M; Cai Z; Zhan P; Liu X; Zhu S; Ye M; Lv T; Lv J; Song Y; Wang D Ther Adv Med Oncol; 2024; 16():17588359231225036. PubMed ID: 38420602 [TBL] [Abstract][Full Text] [Related]
6. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1. Liu J; Liu Y Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773 [TBL] [Abstract][Full Text] [Related]
7. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer. Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917 [TBL] [Abstract][Full Text] [Related]
8. Status of 10 targeted genes of non-small cell lung cancer in eastern China: A study of 884 patients based on NGS in a single institution. Li D; Ding L; Ran W; Huang Y; Li G; Wang C; Xiao Y; Wang X; Lin D; Xing X Thorac Cancer; 2020 Sep; 11(9):2580-2589. PubMed ID: 32729257 [TBL] [Abstract][Full Text] [Related]
9. [Driver genes expression and clinical characteristics of targeted therapy in non-small cell lung cancer in Yunnan-Kweichow Plateau]. Lin YP; Li Q; Ma LY; Liu X; Dai M; Wang XX; Li HS; Liu JX; Shen ZH; Guo YJ; Du YX; Yang RJ; Huang YC; Zhou YC Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):735-740. PubMed ID: 32988155 [No Abstract] [Full Text] [Related]
10. Relationship between driver gene mutations and clinical pathological characteristics in older lung adenocarcinoma. Liu X; Jiang G; Sun X; Su G; Zhang X; Shen D; Yan N Front Oncol; 2023; 13():1275575. PubMed ID: 38023198 [TBL] [Abstract][Full Text] [Related]
11. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests. Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532 [TBL] [Abstract][Full Text] [Related]
12. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer]. Chen LF; Chen XY; Yu XB Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):221-5. PubMed ID: 27033383 [TBL] [Abstract][Full Text] [Related]
13. Genetic Profiling of Non-Small Cell Lung Cancer in Moroccan Patients by Targeted Next-Generation Sequencing. El Zaitouni S; Laraqui A; Ghaouti M; Benzekri A; Kettani F; Boustany Y; Benmokhtar S; Lamrani Alaoui H; El Annaz H; Abi R; Tagajdid MR; El Kochri S; El Mchichi B; Bouaiti EA; Lahlou IA; El Hassani RA; Ennibi K Technol Cancer Res Treat; 2024; 23():15330338241288907. PubMed ID: 39363851 [TBL] [Abstract][Full Text] [Related]
14. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF. Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879 [TBL] [Abstract][Full Text] [Related]
15. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age. Ke L; Xu M; Jiang X; Sun X Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372 [TBL] [Abstract][Full Text] [Related]
16. Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials. Suh JH; Johnson A; Albacker L; Wang K; Chmielecki J; Frampton G; Gay L; Elvin JA; Vergilio JA; Ali S; Miller VA; Stephens PJ; Ross JS Oncologist; 2016 Jun; 21(6):684-91. PubMed ID: 27151654 [TBL] [Abstract][Full Text] [Related]
19. Analysis of multigene detection in patients with advanced lung adenocarcinoma using cytological specimens. Ma Y; Du Y; Wang R; Ji X; Wu J; Liu Y; Guo X; Zhang Y Pathol Res Pract; 2020 Aug; 216(8):153036. PubMed ID: 32703499 [TBL] [Abstract][Full Text] [Related]
20. Investigation of EGFR and ALK mutation frequency and treatment results in advanced non-small cell lung cancer. Komurcuoglu B; Karakurt G; Kaya OO; Diniz G; Kırbıyık O; Evkan A; Yalnız E J Cancer Res Ther; 2023 Apr; 19(Supplement):S183-S190. PubMed ID: 37147996 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]